Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GSK PLC. (GSK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...

The increase comes as investors continue to hedge against geopolitical risks, particularly on fears over the impact of a ...

Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?